VirtualScopics closes $3.8M financing

Article

GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite

GE Medical Systems and affiliates of venture capitalist Trillium Group are the primary contributors of some $3.8 million invested in VirtualScopics as part of that company's Series C round of financing. The Pittsford, NY, provider is developing a suite of image analysis tools that detect and help characterize tiny changes in physical structures over time. The firm's image-based biomarker solutions are designed to accelerate the pharmaceutical R&D process by rapidly measuring the efficacy and safety of drug compounds. The technology might also be leveraged to improve treatment planning and diagnosis for patients. GE plans to collaborate with VirtualScopics to advance the application of its imaging technology in clinical trials. The firm's proprietary software algorithms can assemble hundreds of separate medical images taken during an MRI session into a single 3D model.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.